Gastrointestinal Cancer,Pancreatic Cancer Phase 2 Study: Rucaparib-resistant BRCA/PALB2 Pancreatic Cancer Treatment Mar 27, 2023
Gastric Cancer,Gastrointestinal Cancer Impact of Skipping Bevacizumab on IMBRAVE150 HCC Treatment Efficacy Mar 14, 2023
Gastrointestinal Cancer,Liver Cancer Impact of ADAs on uHCC Treatment in HIMALAYA Phase 3 Study Mar 10, 2023
Gastrointestinal Cancer,Liver Cancer HRQoL Impact of Tislelizumab vs. Sorafenib in First-line uHCC: RATIONALE-301 Mar 10, 2023
Gastrointestinal Cancer,Liver Cancer LEAP-002 Study: Lenvatinib+Pembrolizumab vs Lenvatinib+Placebo in aHCC HRQoL Comparison Mar 10, 2023
Gastrointestinal Cancer,Liver Cancer Phase 3 Trial: Pembrolizumab vs. Placebo for Second-Line HCC Treatment in Asian Patients Mar 10, 2023
Gastrointestinal Cancer,Liver Cancer Cost-effectiveness of HCC treatments: Sintilimab + Bevacizumab vs. Lenvatinib Mar 10, 2023
Gastrointestinal Cancer,Liver Cancer Cabozantinib and Durvalumab Combo Shows Promise for GI Malignancies: CAMILLA Trial Mar 10, 2023